11/26/2024

Mercaptopurine Tablets

Products Affected - Description

- Mercaptopurine tablet, Hikma, 50 mg, bottle, 25 count, NDC 00054-4581-11
- Mercaptopurine tablet, Hikma, 50 mg, bottle, 250 count, NDC 00054-4581-27
- Mercaptopurine tablet, Mylan (Viatris), 50 mg, bottle, 250 count, NDC 00378-3547-25 - discontinued
- Mercaptopurine tablet, Quinn Pharmaceuticals, 50 mg, bottle, 25 count, NDC 69076-0913-02
- Mercaptopurine tablet, Quinn Pharmaceuticals, 50 mg, bottle, 250 count, NDC 69076-0913-25

Reason for the Shortage

- Hikma did not provide a reason for the shortage.
- Mylan discontinued 50 mg tablets in 250 count bottles in December 2023. The 25 count bottles are available.
- Quinn has mercaptopurine tablets on shortage due to manufacturing issues.

Available Products

- Mercaptopurine tablet, Mylan (Viatris), 50 mg, bottle, 25 count, NDC 00378-3547-52

Estimated Resupply Dates

- Hikma has mercaptopurine 50 mg tablets in 25 count and 250 count bottles on allocation.
- Quinn has mercaptopurine 50 mg tablets in 25 count and 250 count bottles on back order and the company cannot estimate a release date.

Updated

Updated November 26, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 8, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.